PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.